We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals

1,707 hedge funds and large institutions have $106B invested in Vertex Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 153 funds opening new positions, 689 increasing their positions, 604 reducing their positions, and 107 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more capital inflows, than outflows

Capital inflows: $17.1B | Capital outflows: $7.51B

43% more first-time investments, than exits

New positions opened: 153 | Existing positions closed: 107

24% more call options, than puts

Call options by funds: $851M | Put options by funds: $684M

14% more repeat investments, than reductions

Existing positions increased: 689 | Existing positions reduced: 604

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

1% more funds holding

Funds holding: 1,682 → 1,707 (+25)

1.63% less ownership

Funds ownership: 95.3% → 93.67% (-1.6%)

Holders
1,707
Holders Change
+25
Holders Change %
+1.49%
% of All Funds
20.71%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.21%
New
153
Increased
689
Reduced
604
Closed
107
Calls
$851​M
Puts
$684​M
Net Calls
+$167​M
Net Calls Change
-⁠$61.8​M

VRTX Hedge Fund Activity: Q1 2026 in Review

1,707 of the 8,244 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2026, worth a combined $106B — down 3.1% from $110B a quarter earlier.

Buyers outnumbered sellers: 153 funds opened new VRTX positions and 107 closed out — a net gain of 46 holders — while 689 added to existing stakes and 604 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.78B. The largest seller was Victory Capital Management, cutting an estimated $685M.

  • 1,707 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2026, up from 1,682 in Q4 2025.
  • Funds reported $106B of Vertex Pharmaceuticals stock for Q1 2026, down 3.1% quarter-over-quarter.
  • 153 funds opened new Vertex Pharmaceuticals positions in Q1 2026 and 107 closed out, a net change of +46 holders.
  • The largest Vertex Pharmaceuticals buyer in Q1 2026 was Capital Research Global Investors, an estimated $1.78B added.
  • The largest Vertex Pharmaceuticals seller in Q1 2026 was Victory Capital Management, an estimated $685M sold.

Based on aggregated 13F filings for Q1 2026.